Showing results (91-100 of 149) with videos related to

Sort By:
Pageof 15
Biological Psychiatry|March 6, 2007
Mu (mu) opioid receptor regulation of ethanol-induced dopamine response in the ventral striatum: evidence of genotype specific sexual dimorphic epistasisMartin O Job, Amanda Tang, F Scott Hall, et al.
Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology|January 13, 2006
Norepinephrine transporter blockade can normalize the prepulse inhibition deficits found in dopamine transporter knockout miceMotoyasu Yamashita, Setsu Fukushima, Hao-wei Shen, et al.
Synapse (New York, N.Y.)|June 21, 2008
Alterations in the levels of heterotrimeric G protein subunits induced by psychostimulants, opiates, barbiturates, and ethanol: Implications for drug dependence, tolerance, and withdrawalNobue Kitanaka, Junichi Kitanaka, F Scott Hall, et al.
Medical Journal of the Islamic Republic of Iran|June 9, 2025
Biochemical and Histopathological Alterations Induced by TramadolHusam Abazid, Nour Alabbas, Alaa Hammad, et al.
Family Medicine|July 12, 2024
Expanding Access to Contraceptive Services in a Family Medicine Residency Clinic: The Rapid Access to Contraception Clinic ModelErika A Sullivan, Kayla Jordanova, Andrew D Curtin, et al.
Cancer Letters|March 22, 2017
The dopamine D3 receptor antagonists PG01037, NGB2904, SB277011A, and U99194 reverse ABCG2 transporter-mediated drug resistance in cancer cell linesNoor Hussein, Haneen Amawi, Chandrabose Karthikeyan, et al.
Behavioural Brain Research|July 19, 2021
Metformin reduces oxandrolone- induced depression-like behavior in rats via modulating the expression of IL-1β, IL-6, IL-10 and TNF-αAlaa M Hammad, Yasmeen A Ibrahim, Sawsan I Khdair, et al.
Alcoholism, Clinical and Experimental Research|February 8, 2011
The μ opioid receptor is not involved in ethanol-stimulated dopamine release in the ventral striatum of C57BL/6J miceVorani Ramachandra, Francis Kang, Christine Kim, et al.
Pharmacology, Biochemistry, and Behavior|July 19, 2018
Tetrabenazine, a vesicular monoamine transporter-2 inhibitor, attenuates morphine-induced hyperlocomotion in mice through alteration of dopamine and 5-hydroxytryptamine turnover in the cerebral cortexNobue Kitanaka, Junichi Kitanaka, F Scott Hall, et al.
The Journal of Pharmacy and Pharmacology|November 15, 2024
Protein phosphatase 2A inhibitors: a possible pharmacotherapy for benzodiazepine dependenceChisa Kobayashi, Nobue Kitanaka, Masanori Nakai, et al.
Pageof 15